PSA and MRI Prostate Cancer Screening | NEJM
Summary
TLDRA study involving 13,153 men aged 50-60 suggests that performing prostate biopsies only in those with elevated PSA levels and MRI-visible lesions could reduce overdiagnosis of clinically insignificant prostate cancer. This approach lowered the risk of detecting such cancers by 57% without missing significant cancers, according to a trial published on NEJM.org.
Takeaways
- 🔍 **Overdiagnosis Issue**: Many prostate cancer diagnoses based on elevated PSA levels may be clinically insignificant and not life-threatening.
- 💉 **PSA and MRI Criteria**: The study focuses on men with elevated PSA levels and visible lesions on MRI for prostate biopsies.
- 👨🔬 **Trial Design**: A randomized, prospective, population-based trial involving 13,153 men aged 50 to 60.
- 📊 **PSA Threshold**: Men with a PSA level of 3 ng/mL or higher underwent prostate MRI.
- 🧬 **Biopsy Methods**: Participants were divided into groups for systematic biopsy with MRI-targeted biopsy or MRI-targeted biopsy alone.
- 🔄 **Screening Frequency**: Repeat screenings were scheduled every 2, 4, or 8 years based on PSA levels.
- 📉 **Risk Reduction**: The MRI-targeted biopsy group had a 57% lower risk of detecting clinically insignificant cancer compared to the systematic biopsy group.
- 🏥 **Clinically Significant Cancer**: The diagnosis rate of clinically significant cancer was similar in both groups.
- 🚑 **Adverse Events**: Five severe adverse events leading to hospitalization occurred, likely related to biopsy procedures.
- 📝 **Conclusion**: Omitting systematic prostate biopsy in men with elevated PSA and negative MRI results reduces overdiagnosis without missing significant cancers.
Q & A
What is the issue with diagnosing prostate cancer based on elevated PSA levels alone?
-Diagnosing prostate cancer based solely on elevated PSA levels can lead to overdiagnosis, where patients are diagnosed with clinically insignificant disease that will never progress to become a threat to their lives.
What is the potential harm of treating clinically insignificant prostate cancer?
-Treating patients with clinically insignificant prostate cancer can result in substantial life-altering side effects without the prospect of extending their lives.
What was the aim of the new study mentioned in the script?
-The aim of the study was to determine whether performing prostate biopsies only in men with elevated PSA levels and visible lesions on MRI could reduce overdiagnosis without missing clinically important prostate cancers.
How many participants were involved in the study?
-The study involved 13,153 men aged 50 to 60 years.
What were the two groups in the study?
-The participants were divided into two groups: one that underwent systematic biopsy and targeted biopsy if suspicious lesions were found on MRI, and another that only underwent MRI-targeted biopsy.
What were the intervals for repeat screenings in the study?
-Repeat screenings occurred every 2, 4, or 8 years, depending on the participants' PSA levels.
What was the median follow-up period for the study?
-The median follow-up period was 3.9 years.
What was the outcome for the MRI-targeted biopsy group regarding the risk of clinically insignificant cancer detection?
-The MRI-targeted biopsy group had a 57% lower risk of clinically insignificant cancer being detected at screening or as interval cancer compared to the systematic biopsy group.
Was there a difference in the diagnosis of clinically significant cancer between the two groups?
-The percentage of men diagnosed with clinically significant cancer was similar in both groups.
What was the incidence of severe adverse events related to biopsy in the study?
-Five severe adverse events leading to hospitalization occurred, with four likely related to biopsy.
What is the conclusion of the study regarding systematic prostate biopsy for men with elevated PSA levels and negative MRI results?
-The study concluded that omitting systematic prostate biopsy for men with elevated PSA levels and negative MRI results reduced diagnoses of clinically insignificant prostate cancer, and the associated risk of having incurable cancer diagnosed at screening or as interval cancer was very low.
Outlines
🏥 Prostate Cancer Overdiagnosis and MRI-Targeted Biopsies
A new study investigates whether performing prostate biopsies only in men with elevated PSA levels and visible lesions on MRI could reduce the overdiagnosis of prostate cancer without missing clinically significant cases. The trial involved 13,153 men aged 50 to 60, who underwent PSA screening and, if their PSA level was 3 ng/ml or higher, an MRI of the prostate. Participants were divided into two groups: one that received both systematic and targeted biopsies if MRI showed suspicious lesions, and another that only received MRI-targeted biopsies. The study found that after a median follow-up of 3.9 years, the MRI-targeted biopsy group had a 57% lower risk of detecting clinically insignificant cancer compared to the systematic biopsy group. However, the diagnosis rate of clinically significant cancer was similar in both groups, and severe adverse events were rare. The study suggests that omitting systematic prostate biopsies for men with elevated PSA levels and negative MRI results could reduce overdiagnosis without increasing the risk of missing significant cancers.
Mindmap
Keywords
💡Prostate-specific antigen (PSA)
💡Overdiagnosis
💡Clinically insignificant disease
💡Systematic biopsy
💡MRI-targeted biopsy
💡Clinically significant cancer
💡Advanced or high-risk cancers
💡Randomized prospective trial
💡Severe adverse events
💡Interval cancer
Highlights
Prostate cancer diagnosed by systematic biopsy based on elevated PSA levels often leads to overdiagnosis of clinically insignificant cases.
Overdiagnosis can result in unnecessary treatments with life-altering side effects, without a prospect of extending patients' lives.
The study explores whether performing prostate biopsies only in men with elevated PSA levels and visible MRI lesions could reduce overdiagnosis.
The trial was a randomized, prospective, population-based study including 13,153 men aged 50 to 60 years.
Men with PSA levels of 3 ng/mL or higher underwent an MRI of the prostate before biopsy decisions.
Participants were divided into two groups: one underwent systematic biopsy, while the other had only MRI-targeted biopsy.
Repeat screenings were scheduled every 2, 4, or 8 years, based on PSA levels.
After a median follow-up of 3.9 years, the MRI-targeted biopsy group had a 57% lower risk of detecting clinically insignificant cancer.
Both groups had similar rates of clinically significant cancer detection, showing that MRI-targeted biopsies didn’t miss important cancers.
Advanced or high-risk prostate cancers were uncommon in both groups.
Five severe adverse events leading to hospitalization were observed, four of which were likely related to the biopsy procedure.
The study concluded that omitting systematic biopsy in men with elevated PSA and negative MRI reduced the diagnosis of clinically insignificant cancer.
The risk of having incurable cancer detected at screening or as interval cancer was very low when systematic biopsy was omitted.
MRI-targeted biopsies appear to be a promising method to reduce overdiagnosis and unnecessary treatments in prostate cancer.
Full trial results and further details are available on the NEJM website.
Transcripts
Many patients with prostate cancer diagnosed by systematic biopsy based on elevated
prostate-specific antigen, or PSA, levels have clinically insignificant disease that
will never progress to become a threat to their lives. This is known as overdiagnosis. Treating
patients with clinically insignificant disease is a source of substantial life-altering side
effects without the prospect of extending lives. A new study asks whether performing
prostate biopsies only in men with elevated PSA levels and visible lesions on MRI could
reduce prostate cancer overdiagnosis without missing clinically important prostate cancers.
In this randomized, prospective, population-based trial, 13,153 men 50 to 60 years of age were
invited to undergo PSA screening, and those with a PSA level of 3 ng per milliliter or
higher underwent MRI of the prostate. Participants were assigned to either a
group that underwent systematic biopsy and, if suspicious lesions were found on MRI,
also underwent targeted biopsy, or a group that only underwent MRI-targeted
biopsy. Repeat screenings occurred every 2, 4, or 8 years, depending on PSA levels.
After a median follow-up of 3.9 years, the MRI-targeted biopsy
group had a 57% lower risk of clinically insignificant cancer being detected at
screening or as interval cancer than the systematic biopsy group. In contrast,
the percentage of men who were diagnosed with a clinically significant cancer was similar in
the two groups, and advanced or high-risk cancers were uncommon. Five severe adverse
events leading to hospitalization occurred, four of which were likely to be related to biopsy.
The authors conclude that among men with elevated PSA levels and negative MRI results,
omitting systematic prostate biopsy reduced diagnoses of clinically insignificant prostate
cancer and the associated risk of having incurable cancer diagnosed at screening
or as interval cancer was very low. Full trial results are available at NEJM.org.
浏览更多相关视频
Is PSA Density Still Relevant? #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
Prostrate Cancer, Causes, Signs and Symptoms, DIagnosis and Treatment.
New Study Shows The Impact of Diet on Prostate Cancer | Mark Scholz, MD | PCRI
So schrumpft deine Prostata in wenigen Monaten | Dr. med. Ingfried Hobert
Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM
2050 तक 93% तक बढ़ जाएंगी पुरुषों में कैंसर से होने वाली मौतें 😱 | जानिए पूरा मामला
5.0 / 5 (0 votes)